<DOC>
	<DOCNO>NCT01488201</DOCNO>
	<brief_summary>This randomize , placebo-controlled , ascend single dose study KHK4827 evaluate safety , tolerability , pharmacokinetics pharmacodynamics subcutaneous intravenous administration KHK4827 healthy male subject moderate severe psoriasis patient .</brief_summary>
	<brief_title>A Clinical Pharmacology KHK4827 Healthy Volunteers Subject With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Health volunteer Able provide write informed consent Healthy male 20 45 year age , inclusive time screen Additional inclusion criterion apply Psoriasis subject 20 70 year age , inclusive time screen Active clinically stable , plaque psoriasis Psoriasis involve ≥10 % body surface area A minimum PASI score ≥10 obtain screening period Additional inclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>